What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cardiology
The scientist’s investigation covers issues in Internal medicine, Cardiology, Myocardial infarction, Endocrinology and Heart failure.
His Internal medicine study frequently intersects with other fields, such as Surgery.
His work in Cardiology is not limited to one particular discipline; it also encompasses Prospective cohort study.
Myocardial infarction connects with themes related to Coronary artery disease in his study.
His studies deal with areas such as Inflammation and Signal transduction as well as Endocrinology.
The concepts of his Heart failure study are interwoven with issues in Placebo and Heart disease.
His most cited work include:
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes (4782 citations)
- Effect of carvedilol on survival in severe chronic heart failure. (2364 citations)
- 2018 ESC/EACTS Guidelines on myocardial revascularization. (2020 citations)
What are the main themes of his work throughout his whole career to date?
Hugo A. Katus mainly investigates Internal medicine, Cardiology, Heart failure, Myocardial infarction and Endocrinology.
As part of his studies on Internal medicine, Hugo A. Katus often connects relevant areas like Surgery.
His research on Cardiology often connects related areas such as Radiology.
His research on Heart failure focuses in particular on Dilated cardiomyopathy.
He most often published in these fields:
- Internal medicine (60.54%)
- Cardiology (47.09%)
- Heart failure (18.55%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (60.54%)
- Cardiology (47.09%)
- Heart failure (18.55%)
In recent papers he was focusing on the following fields of study:
Hugo A. Katus spends much of his time researching Internal medicine, Cardiology, Heart failure, Myocardial infarction and Cell biology.
His multidisciplinary approach integrates Internal medicine and In patient in his work.
His Cardiology study combines topics in areas such as Stroke and Disease.
His Heart failure study incorporates themes from Muscle hypertrophy and Pharmacology.
He is involved in the study of Myocardial infarction that focuses on Troponin T in particular.
His Cell biology research includes elements of Gene expression and Zebrafish.
Between 2017 and 2021, his most popular works were:
- 2018 ESC/EACTS Guidelines on myocardial revascularization. (2020 citations)
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). (1195 citations)
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDThe Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) (719 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Cardiology
Hugo A. Katus mostly deals with Internal medicine, Cardiology, Heart failure, Cell biology and Myocardial infarction.
Stroke, Ejection fraction, Hazard ratio, Cardiomyopathy and Coronary artery disease are the primary areas of interest in his Internal medicine study.
His Cardiology research focuses on MEDLINE and how it relates to Takotsubo syndrome.
His Heart failure research incorporates elements of Mitral valve, Hemodynamics and Mitral regurgitation.
The Cell biology study combines topics in areas such as Transgene, Patch clamp, Gene expression and Gene knockdown.
His is doing research in Acute coronary syndrome, Troponin, Ticagrelor and Clopidogrel, both of which are found in Myocardial infarction.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
